Peripheral Metabolic Effects Beyond glucose regulation, GLP2 influences multiple metabolic parameters: Improved insulin sensitivity markers including HOMA2-IR reductions Favorable effects on lipid profiles with reductions in triglycerides and LDL cholesterol Decreased liver enzyme levels suggesting hepatic metabolic improvements Increased insulin-like growth factor binding proteins (IGFBP1 and IGFBP2) [CALLOUT BOX Highlighted] Key Mechanistic Insight: GLP2s imbalanced dual agonism stronger GIP receptor activation combined with biased GLP-1 receptor signaling creates a unique pharmacological profile distinct from selective GLP-1 receptor agonists
Kratzsch J, Lammert A, Bottner A, Seidel B, Mueller G, Thiery J et al
Popular branded versions include: Ozempic (semaglutide) : Approved for Type 2 diabetes Wegovy (semaglutide) : Approved for chronic weight management Mounjaro (tirzepatide) : Newer dual-action drug also making waves GLP-1 drugs are typically injected weekly and have been shown to reduce blood sugar levels and body weight dramatically
The most commonly reported events were decreased appetite (19%), headache (12%), fatigue (11%), and COVID-19 infection (11%), most of which were mild
Results Patient population We included 78,781 patients who had both a prescription for a GLP-1 receptor agonist (GLP-1 RA) and a documented reason for discontinuing the medication between June 2021 and December 2024 (Table 1)
